Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
Study sponsor: ACADIA Pharmaceuticals Inc. · ACAD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-09-27Actual
Enrollment · participants237Actual
Source updated2025-08-24Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.